{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:00Z","timestamp":1791288540194,"version":"4.3.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to evaluate the cost-effectiveness of tenofovir alafenamide fumarate (TAF) versus tenofovir disoproxil fumarate (TDF) for chronic hepatitis B treatment from a payer\u2019s perspective in a limited-income context like Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was developed to estimate the lifetime cost and effectiveness (measured in quality-adjusted life year, QALY) of TAF compared to TDF in the HbeAg+ patient population. Efficacy data came from clinical trials, and costs were based on 2023 data from an exit survey of 94 inpatients and 464 outpatients in Bach Mai hospital. Other clinical data were also sourced from CHB patients at Bach Mai hospital. Along with deterministic analysis, two-way sensitivity analysis, probabilistic sensitivity analysis, threshold, and budget impact analysis were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to TDF, TAF yielded an additional cost of USD 3,983 and an additional QALY gained of 0.14, resulting in the incremental cost-effectiveness ratio (ICER) of USD 32,090 per QALY gained. The ICER exceeds the cost-effective threshold of three-time gross domestic product (GDP) per capita, that is, USD 11,348, by 2.8 times. According to one-way sensitivity analysis, ICERs were driven mainly by transition probabilities and TDF\/ TAF prices. TAF would be cost-effective compared to TDF at the three-time GDP per capital threshold if TAF price were reduced by 33.4%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TAF is not cost-effective compared to TDF for treating chronic hepatitis B in HBeAg+ patients. The study offers relevant evidence for policymakers to consider including TAF in the social health insurance package, with a focus on price negotiation. Future updates are needed as new evidence on the effectiveness and costs of treating chronic hepatitis B emerges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535251349054","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:53:21Z","timestamp":1749297201000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam"],"prefix":"10.1177","volume":"30","author":[{"given":"Tran Dieu","family":"Thuy","sequence":"first","affiliation":[{"name":"Bach Mai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-3688","authenticated-orcid":false,"given":"Nguyen Thu","family":"Ha","sequence":"additional","affiliation":[{"name":"Health Management Training Institute, Hanoi University of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Duy","family":"Cuong","sequence":"additional","affiliation":[{"name":"Bach Mai Hospital"},{"name":"Vietnam National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Van","family":"Long","sequence":"additional","affiliation":[{"name":"Bach Mai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-7971","authenticated-orcid":false,"given":"Nguyen Quynh","family":"Anh","sequence":"additional","affiliation":[{"name":"Health Management Training Institute, Hanoi University of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"Snapshot [Internet]. [cited 2024 Aug 29]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61412-X"},{"key":"e_1_3_7_4_2","unstructured":"Ngoc Thi Trinh. Overview of hepatitis situation in Vietnam [Internet]. [cited 2023 Jun 21]. Available from: https:\/\/vasld.com.vn\/tong-quan-tinh-hinh-viem-gan-tai-viet-nam"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2018.06.010"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.12.001"},{"key":"e_1_3_7_9_2","unstructured":"Vietnam Ministry of Health. Decision No. 3310\/QD-BYT dated July 29 2019: Promulgating guidelines for diagnosis and treatment of viral hepatitis B. Hanoi: Vietnam Ministry of Health 2019."},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14848"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14155"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_3_7_13_2","unstructured":"CADTH Canadian Drug Expert Committee Recommendation: Tenofovir Alafenamide (Vemlidy - Gilead Sciences Canada Inc.): Indication: chronic hepatitis B [Internet]. Ottawa (ON): Canadian agency for drugs and technologies in health; 2018 Mar 28. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532703\/"},{"key":"e_1_3_7_14_2","first-page":"265","volume-title":"Statistical yearbook of Vietnam 2023","author":"General Statistics Office","year":"2023","unstructured":"General Statistics Office. Statistical yearbook of Vietnam 2023. : Statistical publishing house, 2023, p. 265."},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.06.024"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00852-y"},{"key":"e_1_3_7_17_2","volume-title":"National guideline in health technology assessment. Hanoi","author":"Vietnam Health Strategic and Planning Institute","year":"2022","unstructured":"Vietnam Health Strategic and Planning Institute. National guideline in health technology assessment. Hanoi. Medical Publishing House, 2022."},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9741-6"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"issue":"3","key":"e_1_3_7_21_2","first-page":"324","article-title":"3-year treatment of tenofovir alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"Hou J","year":"2021","unstructured":"Hou J, Ning Q, Duan Z, et al. 3-year treatment of tenofovir alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China. J Clin Transl Hepatol 2021; 9(3): 324\u2013334.","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23348"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31347-8"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03813.x"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00019"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305517"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.031"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29874"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep42253"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120411"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis569"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00297.x"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2012.03.008"},{"key":"e_1_3_7_34_2","unstructured":"108 liver transplants in 4 years will build an artificial heart transplant project [Internet]. [cited 2023 Dec 14]. Available from: https:\/\/cand.com.vn\/y-te\/108-ca-ghep-gan-trong-4-nam-se-xay-dung-de-an-ghep-tim-nhan-tao-i642207\/"},{"key":"e_1_3_7_35_2","unstructured":"Vietnam Ministry of Health. Decision No. 4531\/QD-BYT dated September 24 2021: Promulgating the national plan on treatment and control of viral hepatitis disease in Vietnam period 2021-2025. Hanoi: Vietnam Ministry of Health. 2021."},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108051"},{"key":"e_1_3_7_37_2","unstructured":"The estimated budget for health insurance examination and treatment in 2021 is over 106 trillion VND. [Internet]. 2021 [cited 2024 Oct 14]. Available from: https:\/\/baochinhphu.vn\/giao-du-toan-chi-kham-chua-benh-bhyt-nam-2021-hon-106-nghin-ty-dong-102290058.htm"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0090"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321309"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1323633"},{"key":"e_1_3_7_42_2","unstructured":"World Health Organization. Life tables by country: Vietnam [Internet]. Geneva: World Health Organization. 2020. [cited 2024 Apr 28]. Available from: https:\/\/apps.who.int\/gho\/data\/view.searo.61830?lang=en"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535251349054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535251349054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535251349054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:24Z","timestamp":1777380804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535251349054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/13596535251349054"],"URL":"https:\/\/doi.org\/10.1177\/13596535251349054","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"13596535251349054"}}